Latest news
Alterity CEO Set to Present at Canaccord Growth Conference - Stock TitanStock Titan · Thu, 06 Aug 2026 11:25:00 GMTAlterity Therapeutics (NASDAQ: ATHE) plans Canaccord Growth Conference talk - Stock TitanStock Titan · Thu, 06 Aug 2026 10:06:42 GMT[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - Stock TitanStock Titan · Tue, 04 Aug 2026 10:04:51 GMTPRNAF SEC Filings - ALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Forms - Stock TitanStock Titan · Sun, 02 Aug 2026 18:32:08 GMTAlterity Therapeutics (NASDAQ: ATHE) outlines FDA-backed Phase 3 plan for ATH434 - Stock TitanStock Titan · Thu, 30 Jul 2026 10:05:21 GMTAlterity’s ATH434 Trial for Rare MSA May Enroll 200 Patients - Stock TitanStock Titan · Thu, 30 Jul 2026 07:00:00 GMTAlterity Therapeutics (NASDAQ: ATHE) sets August 31, 2026 expiry for 18.4M ATHO options - Stock TitanStock Titan · Wed, 29 Jul 2026 10:06:31 GMT